건강과 대안 » (herpes simplex virus 1 and 2 http://www.chsc.or.kr 연구공동체 Fri, 12 Jun 2026 00:11:00 +0000 ko-KR hourly 1 http://wordpress.org/?v=3.5.2 [학술논문] 감염성 존재량과 뇌졸중 위험 http://www.chsc.or.kr/?post_type=reference&p=1287 http://www.chsc.or.kr/?post_type=reference&p=1287#comments Wed, 11 Nov 2009 16:42:21 +0000 건강과대안 http://www.chsc.or.kr/?post_type=reference&p=1287 감염성 존재량과 뇌졸중 위험(Infectious Burden and Risk of Stroke)

미첼 엘킨드(컬럼비아대학 메디칼센터, 신경과전문의) 박사팀이 [신경학 기록(Archives of Neurology)]에 기고한 논문입니다.

뉴욕의 맨하튼에 거주하는 1625명이 성인(평균연령 68.4세)을 평균 7.6년동안 5가지 전염병 원인체에 대한 혈청학적 조사 분석해본 결과라고 합니다. 조사기간 동안 뇌졸증이 나타난 환자들의 대다수가 5가지 중에서 1가지 이상의 병원체에 감염된 것으로 밝혀졌다고 합니다.

혈청학적 조사 분석 대상 5가지 병원체는 클라미디아 폐렴균(Chlamydia pneumoniae), 헬크코박터 파일로리균(Helicobacter pylori), 사이토메갈로바이러스(cytomegalovirus), and 단순포진 바이러스 1, 2(herpes simplex virus 1 and 2)였습니다.

이러한 결과는 뇌졸증과 병원체의 연관 가능성을 시사하는 것이지만… 연구자들은 병원체들이 동맥기능에 어떤 손상을 입히는지를 명확히 규명하지는 못했습니다. 교신저자인 미첼 엘킨드 박사는 언론과 인터뷰에서 “만성감염이 혈관에 염증을 일으켜 혈류를 위축시키거나 병원균 자체가 동맥벽의 기능을 손상시키기 때문”에 뇌졸증을 유발하는 것으로 추정한다고 밝혔습니다.

==================================

Infectious Burden and Risk of Stroke

The Northern Manhattan Study

Mitchell S. V. Elkind, MD, MS; Pankajavalli Ramakrishnan, MD, PhD; Yeseon P. Moon, MS; Bernadette Boden-Albala, DrPH; Khin M. Liu, BS; Steve L. Spitalnik, MD, PhD; Tanja Rundek, MD, PhD; Ralph L. Sacco, MD, MS; Myunghee C. Paik, PhD

출처 : Arch Neurol. 2010;67(1):(doi:10.1001/archneurol.2009.271).
http://archneur.ama-assn.org/cgi/content/full/2009.271?home

ABSTRACT





Objective  To determine the association between a composite measure of serological test results for common infections (Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus 1 and 2) and stroke risk in a prospective cohort study.


Design  Prospective cohort followed up longitudinally for median 8 years.

Setting  Northern Manhattan Study.

Patients  Randomly selected stroke-free participants from a multiethnic urban community.

Main Outcome Measure  Incident stroke and other vascular events.

Results  All 5 infectious serological results were available from baseline samples in 1625 participants (mean [SD] age, 68.4 [10.1] years; 64.9% women). Cox proportional hazards models were used to estimate associations of each positive serological test result with stroke. Individual parameter estimates were then combined into a weighted index of infectious burden and used to calculate hazard ratios and confidence intervals for association with risk of stroke and other outcomes, adjusted for risk factors. Each individual infection was positively, though not significantly, associated with stroke risk after adjusting for other risk factors. The infectious burden index was associated with an increased risk of all strokes (adjusted hazard ratio per standard deviation, 1.39; 95% confidence interval, 1.02-1.90) after adjusting for demographics and risk factors. Results were similar after excluding those with coronary disease (adjusted hazard ratio, 1.50; 95% confidence interval, 1.05-2.13) and adjusting for inflammatory biomarkers.

Conclusions  A quantitative weighted index of infectious burden was associated with risk of first stroke in this cohort. Future studies are needed to confirm these findings and to further define optimal measures of infectious burden as a stroke risk factor.




INTRODUCTION

Stroke is the third leading cause of death in the United States and the leading cause of serious disability.1 Classic modifiable risk factors include hypertension, cardiac disease, dyslipidemia, and smoking, but many strokes occur in patients without any of these risk factors.1 There is therefore interest in identifying additional modifiable stroke risk factors. Seroepidemiological studies in patients with coronary artery disease and stroke have provided evidence of an association of risk with serological evidence of prior infections with various pathogens such as Chlamydia pneumoniae, Helicobacter pylori, and herpesviruses.2-8 In addition, several of these organisms have been identified in atherosclerotic tissue specimens, and some have been found capable of inducing atherosclerosis in animal models.9-10


Mechanistically, these pathogens are thought to promote inflammation, thus contributing to atherosclerosis.11-12 Prospective studies and meta-analyses, however, have suggested that the association of individual serological test results with risk of vascular events is modest.2 A more likely scenario is that a composite measure of multiple serological results, or infectious burden (IB), is associated with risk.13-16 According to this hypothesis, the greater the number of infectious exposures during one’s lifetime, the higher the chance of promoting atherosclerosis via inflammation, thus increasing the risk of cardiovascular disease. Some investigators have provided support for this concept by correlating the number of positive serological test results with the presence of atherosclerosis and carotid plaque progression or risk of vascular events, including stroke.13-15,17 In these studies, however, all positive serological test results are given equal weight in predictive models. It is plausible, however, that different infections would each carry different weights of association with risk of vascular disease.

We hypothesized that a weighted measure of IB would be associated with risk of incident stroke in a prospective cohort study in a multiethnic urban adult population. We further hypothesized that this same weighted measure would also be associated with other vascular event outcomes.


METHODS

PARTICIPANT SELECTION


The Northern Manhattan Study is a community-based prospective cohort study designed to investigate stroke incidence, risk factors, and predictors of severity and outcome, as described previously.18-19 Briefly, this is a stroke-free, multiethnic, urban population with a race/ethnic distribution of 63% Hispanic, 20% non-Hispanic black, and 15% non-Hispanic white participants who were recruited by random-digit dialing. A total of 3298 participants were enrolled between 1993 and 2001 if they (1) had no prior diagnosis of stroke, (2) were older than 39 years, and (3) resided in northern Manhattan, New York, for at least 3 months in a household with a telephone. All participants gave informed consent and the study was approved by Columbia University Medical Center institutional review board.

Baseline data were obtained via interviews with bilingual research assistants, physical and neurological examination by study physicians, inpatient assessments, and fasting blood specimen analysis.18 Blood pressure, height, weight, fasting lipid panels, leukocyte count, and glucose level were measured by standard techniques. High-sensitivity C-reactive protein (hsCRP) level was measured using a BNII nephelometer (Dade-Behring, Deerfield, Illinois). Hypertension (history, taking medications, or systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) and diabetes mellitus (history, taking medications, or fasting blood glucose level ≥126 mg/dL [to convert to millimoles per liter, multiply by 0.0555]) were defined as described previously.19 Blood samples collected at enrollment were centrifuged and frozen at –70°C in 1-mL aliquots until the time of analysis. Because not all participants had sufficient blood samples available for the multiple serological analyses required for this study, a subsample of 1625 participants was used for the present analyses.

SEROLOGICAL ANALYSES

Serological test results against 5 common pathogens that have each been linked to atherosclerotic disease in prior studies were assessed. Enzyme-linked immunoassay was used to measure antibody titers against C pneumoniae (Savyon Diagnostics, Ashdod, Israel), H pylori, cytomegalovirus (CMV) (Wampole Laboratories, Princeton, New Jersey), and herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) (Focus Diagnostics, Cypress, California). Both IgG and IgA titers were measured for C pneumoniae, but based on previous results in our population5-6 and others,3 IgA titers were used for further analyses. IgG titers were assessed for the other pathogens. Positive serological test results were based on recommendations from the commercial laboratories providing the assays. All serological testing was conducted by personnel blinded to clinical outcomes.

FOLLOW-UP ASSESSMENTS

Annual follow-up conducted by telephone included assessment of vital status (dead or alive), interval hospitalizations, and presence of symptoms and events consistent with stroke or myocardial infarction (MI) as previously described.18-19 Strokes were independently classified by 2 neurologists according to a modified Stroke Data Bank scheme,20 with subtype assessments determined by consensus. Disagreements were adjudicated by a third neurologist evaluator. A study cardiologist reviewed MIs for validation. First presentation of any type of stroke, ischemic or hemorrhagic, was defined according to the criteria established by the World Health Organization. Myocardial infarction was defined by criteria specified by the Cardiac Arrhythmia Pilot Study21 and the Lipid Research Clinics Coronary Primary Prevention Trial.22 All deaths were verified by a study physician and classified as vascular (stroke, MI, heart failure, pulmonary embolus, cardiac arrhythmia, and other vascular causes) or nonvascular.

STATISTICAL ANALYSES

The primary end point was all strokes; secondary end points were ischemic stroke, MI, vascular deaths, nonvascular deaths, all deaths, and a combined end point of stroke, MI, and vascular death. First, Cox proportional hazards models were used to estimate the regression coefficients and 95% confidence intervals (CIs) for the association of each individual serological test result with risk of stroke in unadjusted models and models adjusted for demographics, blood pressure, coronary artery disease, waist size, alcohol consumption, physical activity, smoking, and levels of blood glucose, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. We included variables in multivariate models that were significant in prior analyses of vascular outcomes in the Northern Manhattan Study and that are traditionally accepted risk factors for stroke. We used continuous measures for blood pressure and blood glucose level rather than cruder dichotomous measures such as hypertension and diabetes in our main models based on evidence of continuous relationships between these physiologic measures and risk of vascular disease.23 Additional models were run using hypertension and diabetes mellitus as categorical variables.

Parameter estimates, or β coefficients, from a model containing only the individual serological test results were then used to derive a weighted index designated as the IB. Each parameter estimate represents the strength of the association between the individual positive serological test result and stroke as an outcome. Individual parameter estimates for positive serological test results were added together to form the IB index. Parameter estimates for negative serological test results would not be counted toward the total index score. For example, the IB for a participant with individual positive serological results for CMV and HSV-2 would equal the sum of the parameter estimates for only CMV and HSV-2. This index was then used as the independent variable in unadjusted and adjusted models to calculate the hazard ratios (HRs) and CIs for association with risk of stroke and other outcomes. Further models were calculated among those without history of MI. The final models among those without MI satisfied proportionality assumptions. Associations were expressed per change in standard deviation of IB.


RESULTS

Characteristics among the 1625 participants with serological data are shown in Table 1 and were similar to those in the overall Northern Manhattan Study cohort, with the exception that the participants in this study had enrolled later compared with those who did not have all 5 infectious serological results at the time of enrollment. Mean (SD) age of participants was 68.4 (10.1) years, and the median follow-up was 7.6 years (interquartile range, 6.4-9.0 years). In follow-up, there were 67 strokes, of which 56 were ischemic; 98 MIs; 150 vascular deaths; 215 nonvascular deaths; and 390 deaths of all causes. Frequencies of positive serological results, using prespecified thresholds, for C pneumoniae, H pylori, CMV, HSV-1, and HSV-2 are given in Table 1. Positive titers were common for these organisms, ranging from 55% for H pylori to 86% for HSV-1.
















View this table:
[in this window]
[in a new window]
[as a PowerPoint slide]
 




Table 1. Participant Characteristics



Each infectious serological result was positively associated with an increased risk for all strokes, with HRs adjusted for age, sex, race/ethnicity, high school education, systolic blood pressure, low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol level, blood glucose level, moderate to heavy activity level, waist size, and coronary artery disease ranging between 1.13 for H pylori to 2.19 for CMV, although none of these associations reached statistical significance (Table 2).
















View this table:
[in this window]
[in a new window]
[as a PowerPoint slide]
 




Table 2. Risk of Stroke Associated With Positive Serological Results for C pneumoniae, H pylori, CMV, HSV-1, and HSV-2



To determine whether composite seropositivity was associated with risk of stroke, individual unadjusted parameter estimates were added, as earlier, to generate the weighted IB index (mean [SD], 1.00 [0.33]; median, 1.08). The mean [SD] IB index for those with positive results for each serological test is shown in the Figure. The mean IB index was higher in non-Hispanic black (1.05 [0.31]) and Hispanic (1.07 [0.27]) individuals compared with non-Hispanic white individuals (0.75 [0.41]; P < .001 for both comparisons). It was slightly higher in women (1.02 [0.31]) than men (0.97 [0.36]; P = .002). There was no difference by age.
















Figure 1
View larger version (23K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 




Figure. Mean infectious burden index (IBI) by serological status for each of the 5 infections. CMV indicates cytomegalovirus; C pneumoniae, Chlamydia pneumoniae; H pylori, Helicobacter pylori; HSV, herpes simplex virus.



Infectious burden was associated with risk of stroke (unadjusted HR per standard deviation, 1.39; 95% CI, 1.04-1.87), and the effect was essentially unchanged after adjusting for demographics (adjusted HR, 1.42; 95% CI, 1.04-1.94) (Table 3). After adjusting for age, sex, race/ethnicity, high school education, systolic blood pressure, low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol level, blood glucose level, moderate to heavy activity level, waist size, and coronary artery disease, the association remained (adjusted HR, 1.39; 95% CI, 1.02-1.90). Further adjusting for leukocyte count and hsCRP level had no effect on this estimate. The magnitude of the correlation of hsCRP level with IB index was only modest (r = 0.09; P < .001).
















View this table:
[in this window]
[in a new window]
[as a PowerPoint slide]
 




Table 3. Risk of Stroke Associated With IB Index



Additional models were run using history of hypertension and diabetes mellitus, as previously defined,19 in place of blood pressure and blood glucose measurements, and the results were essentially unchanged (adjusted HR per standard deviation change in IB, 1.42; 95% CI, 1.03-1.97). Further analyses limited to those without history of MI (n = 1525) showed a modestly increased magnitude of effect (fully adjusted HR per standard deviation, 1.50; 95% CI, 1.05-2.13).

Tests for interactions with age, sex, race/ethnicity, and other risk factors demonstrated a significant interaction with diabetes mellitus (P = .02). Among diabetic individuals, there was an increased risk of stroke associated with IB (adjusted HR per standard deviation, 1.63; 95% CI, 1.16-2.29). The effect in nondiabetic individuals was reduced in magnitude and not statistically significant (adjusted HR per standard deviation, 1.29; 95% CI, 0.94-1.78). Other interactions were not significant.

All secondary end points were positively associated with IB. Nonvascular deaths (adjusted HR per standard deviation, 1.23; 95% CI, 1.04-1.45) and the combined end point of all stroke, MI, and deaths (adjusted HR per standard deviation, 1.15; 95% CI, 1.03-1.29) reached statistical significance (Table 4).
















View this table:
[in this window]
[in a new window]
[as a PowerPoint slide]
 




Table 4. Risk of Secondary Outcomes Associated With IB




COMMENT

In this prospective cohort study, a weighted index of exposure to 5 common infections previously implicated in atherosclerotic disease was associated with risk of first stroke. Although individually each infection was positively associated with increased stroke risk, none were individually statistically significant. Our measure of IB considered the association of infections with stroke risk as a weighted measure rather than simply summing up the number of positive serological results, as had been done in prior studies. We therefore did not have an a priori assumption about the strength of association between each of the individual infections and stroke risk. These results need to be validated in independent populations, however, before they can be generalized. These results provide evidence that there is probably no single infectious agent responsible for atherosclerosis or stroke, but that a more likely mechanism for any possible association of infection with stroke is through a more general proinflammatory mechanism.


The rationale for investigating these particular 5 pathogens is multifold. First, each of these common pathogens may persist after an acute infection and thus contribute to perpetuating a state of chronic, low-level infection. Second, prior studies demonstrated an association between each of these pathogens and cardiovascular diseases.2-12 C pneumoniae, the best studied of these infections in relation to atherosclerosis, is an atypical respiratory pathogen that has been investigated as a stroke risk factor in several case-control and prospective studies, with mixed results. In prior case-control studies from the northern Manhattan population, C pneumoniae IgA titers were associated with increased stroke risk, though IgG titers were not.5-6 Studies in other populations have similarly found IgA to be a better marker of stroke risk than IgG titers.3 These results have not been confirmed in other studies, however, and prospective studies have demonstrated at best a very modest association of C pneumoniae titers with stroke risk.2 Our present prospective study confirms that the effect of C pneumoniae IgA titers is likely to be modest. Further studies in large populations using well-standardized assays with generally accepted titer cutoffs may be needed to more definitively elucidate the relationship between C pneumoniae and stroke.2

Recent studies have implicated H pylori, which is well recognized as a cause of chronic gastric inflammation, ulceration, and cancer,24 as another pathogen whose persistence might be associated with increased stroke risk. Several case-control studies have demonstrated an increased risk of stroke in seropositive subjects.25-27 A meta-analysis of case-control studies on H pylori serostatus revealed an increased risk for stroke (odds ratio, 1.41; 95% CI, 1.11-1.78), and especially for large-vessel stroke.28 The stroke risk appeared to be especially apparent in subjects seropositive for strains with the virulence factor cytotoxin-associated gene product A (CagA) toxin.28 Other studies have not found this association, however.8, 17, 29-30 We did not limit our analyses to large-vessel stroke, however, nor did we measure H pylori CagA toxin serostatus.

Cytomegalovirus is a common viral pathogen, and it can reactivate and cause particularly severe complications in immunocompromised hosts, though even immunocompetent hosts can develop CMV disease. Cytomegalovirus has been implicated as a cause of transplant vasculopathy.31-32 There is also some evidence that CMV is associated with stroke risk in otherwise healthy individuals. In 2 case-control studies, CMV seropositivity was associated with increased stroke risk,33-34 though this was not confirmed in several prospective studies.7, 17, 35-36 It has been shown that in immunocompromised hosts such as those with diabetes,37 or in post–renal transplant patients,31 the risk of atherosclerotic events including strokes is increased with CMV seropositivity. Cytomegalovirus was most strongly associated with stroke risk among the 5 pathogens we studied, though it did not reach statistical significance. Many of our participants (21%) had diabetes, and this may have influenced our findings.

Herpes simplex virus 1 and HSV-2 are also viral pathogens with chronic persistence in a latent state. Early work on Marek disease virus, a type of chicken herpesvirus, demonstrated that the virus was associated with atherosclerosis in a chicken model.38 Few studies have investigated the association of HSV with stroke risk, and their findings are conflicting. In 1 case-control study, HSV-1 was associated with increased stroke risk,34 but in another nested case-control study, neither HSV-1 nor HSV-2 increased stroke risk.7 As with CMV, immunocompetent status, even when associated with diabetes, might be a confounding factor.

Our results extend the findings of previous prospective studies aimed at investigating the association of IB and other vascular events. In a secondary analysis of the Heart Outcomes Prevention Evaluation trial, combined serostatus for 4 pathogens vs zero to 1 pathogen was associated with risk of MI, stroke, or cardiovascular death with a magnitude similar to what we found (HR, 1.41; 95% CI, 1.02-1.96).15 In that study, however, pathogen burden was not associated with stroke as an independent outcome. In the Framingham study, pathogen burden based on serostatus for C pneumoniae, H pylori, and CMV was not associated with pooled primary end points of MI, atheroembolic stroke, and coronary heart disease death.17 A small case-control study did show a modest association between pathogen burden based on serological results for Legionella pneumophila, Mycoplasma pneumoniae, and C pneumoniae and risk of stroke and transient ischemic attack.39 However, other small case-control studies investigating the pathogen burden using similar serological results did not find an increased risk for stroke, though they may have been underpowered.8, 34

There are several differences between our study and these other studies. Most importantly, our weighted measure of IB avoided a priori assumptions about the strength of association between each of the individual infections and stroke risk. Our study also included HSV-1 and HSV-2 serostatus in the calculation of the IB index, which may have enhanced the ability to detect its influence on first stroke. Small sample size, selection bias, and case-control study design may account for some of the other differences. The Heart Outcomes Prevention Evaluation trial, moreover, was a secondary prevention trial rather than a population-based study.

Our study also explored the association between IB and secondary vascular outcomes. Nonvascular deaths and the combined end point of all stroke, MI, and death were associated with the IB index, though MI and vascular death were not. Studies of periodontal infection and vascular disease have similarly found that there may be a stronger association for stroke than for MI.40-41

Our study could have potential clinical implications. For example, treatment and eradication of these chronic pathogens might mitigate future risk of stroke. Antibiotic therapy directed against C pneumoniae has been tested in randomized controlled trials without evidence of benefit against heart disease.42-43 Whether the same holds true for stroke has not yet been established. More studies will be required to further explore IB as a potential modifiable risk factor for stroke.

Our study has several strengths. First, this was a large, multiethnic, population-based prospective study with routine assessment of risk factors and minimal loss to follow-up. We had a large proportion of Hispanic individuals, a traditionally understudied group, in our population. Incidence of first stroke was assessed after adjusting for traditional risk factors, as well as for hsCRP level and white blood cell count, variables previously shown to be associated with incident stroke.19, 44 The limitations of our study include that participant information regarding the use of specific cholesterol-lowering agents such as statins, preexisting inflammatory diseases, anti-inflammatory medication use, immunosuppression status, and infection status at the time of stroke or other outcomes was unavailable. Availability of these data could have better accounted for known and other unknown confounding factors. Further studies will be needed to confirm the independent predictive effect of IB as a stroke risk factor.


AUTHOR INFORMATION

Correspondence: Mitchell S. V. Elkind, MD, MS, Neurological Institute, 710 W 168th St, Box 182, New York, NY 10032 (mse13@columbia.edu

).


Accepted for Publication: May 31, 2009.

Published Online: November 9, 2009 (doi:10.1001/archneurol.2009.271).

Author Contributions: Dr Elkind had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Elkind, Rundek, Sacco, and Paik. Acquisition of data: Elkind, Boden-Albala, Liu, Spitalnik, and Rundek. Analysis and interpretation of data: Elkind, Ramakrishnan, Moon, Boden-Albala, Rundek, Sacco, and Paik. Drafting of the manuscript: Elkind and Ramakrishnan. Critical revision of the manuscript for important intellectual content: Elkind, Moon, Boden-Albala, Liu, Spitalnik, Rundek, Sacco, and Paik. Statistical analysis: Moon and Paik. Obtained funding: Elkind and Sacco. Administrative, technical, and material support: Elkind, Ramakrishnan, Boden-Albala, Liu, Spitalnik, Rundek, and Sacco. Study supervision: Elkind, Spitalnik, Rundek, and Sacco.

Financial Disclosure: None reported.

Funding/Support: This research was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke grants R37 29993 (Drs Elkind and Sacco) and R01 48134 (Dr Elkind).

Author Affiliations: Departments of Neurology (Drs Elkind and Boden-Albala and Ms Moon) and Pathology and Cell Biology (Ms Liu and Dr Spitalnik), College of Physicians and Surgeons, and Department of Biostatistics, Joseph P. Mailman School of Public Health (Dr Paik), Columbia University, New York, New York; Department of Neurology, Massachusetts General Hospital, Boston (Dr Ramakrishnan); and Departments of Neurology (Drs Rundek and Sacco) and Epidemiology and Genetics (Dr Sacco), Miller School of Medicine, University of Miami, Miami, Florida.


REFERENCES

1. Goldstein LB, Adams R, Alberts MJ; et al, American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(6):1583-1633. FREE FULL TEXT



2. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288(21):2724-2731. FREE FULL TEXT



3. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27(12):2207-2210. FREE FULL TEXT



4. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke. 1998;29(2):404-410. FREE FULL TEXT



5. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2000;31(7):1521-1525. FREE FULL TEXT



6. Elkind MS, Tondella ML, Feikin DR, Fields BS, Homma S, Di Tullio MR. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke. 2006;37(3):790-795. FREE FULL TEXT



7. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998;98(25):2796-2799. FREE FULL TEXT



8. Heuschmann PU, Neureiter D, Gesslein M; et al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke. 2001;32(10):2253-2258. FREE FULL TEXT



9. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997;65(11):4832-4835. ABSTRACT



10. Muhlestein JB, Anderson JL, Hammond EH; et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97(7):633-636. FREE FULL TEXT



11. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 1999;100(4):e20-e28. PUBMED



12. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34(10):2518-2532. FREE FULL TEXT



13. Espinola-Klein C, Rupprecht HJ, Blankenberg S; et al, AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105(1):15-21. FREE FULL TEXT



14. Espinola-Klein C, Rupprecht HJ, Blankenberg S; et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33(11):2581-2586. FREE FULL TEXT



15. Smieja M, Gnarpe J, Lonn E; et al, Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(2):251-257. FREE FULL TEXT



16. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103(1):45-51. FREE FULL TEXT



17. Haider AW, Wilson PW, Larson MG; et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol. 2002;40(8):1408-1413. FREE FULL TEXT



18. Sacco RL, Anand K, Lee HS; et al. Homocysteine and the risk of ischemic stroke in a tri-ethnic cohort: the Northern Manhattan Study. Stroke. 2004;35(10):2263-2269. FREE FULL TEXT



19. Elkind MSV, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL. Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology. 2005;64(12):2121-2125. FREE FULL TEXT



20. Gan R, Sacco RL, Kargman DE, Roberts JK, Boden-Albala B, Gu Q. Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology. 1997;48(5):1204-1211. FREE FULL TEXT



21. Greene HL, Richardson DW, Barker AH; et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol. 1989;63(1):1-6. PUBMED



22. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease: the Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA. 1994;272(18):1439-1441. FREE FULL TEXT



23. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324(7353):1570-1576. FREE FULL TEXT



24. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ. 1994;150(2):177-185. ABSTRACT



25. Park MH, Min JY, Koh SB; et al. Helicobacter pylori infection and the CD14 C(-260)T gene polymorphism in ischemic stroke. Thromb Res. 2006;118(6):671-677. PUBMED



26. Sawayama Y, Ariyama I, Hamada M; et al. Association between chronic Helicobacter pylori infection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT). Atherosclerosis. 2005;178(2):303-309. PUBMED



27. Masoud SA, Arami MA, Kucheki E. Association between infection with Helicobacter pylori and cerebral noncardioembolic ischemic stroke. Neurol India. 2005;53(3):303-307. PUBMED



28. Cremonini F, Gabrielli M, Gasbarrini G, Pola P, Gasbarrini A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis. 2004;173(2):253-259. PUBMED



29. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart. 1996;75(6):568-572. FREE FULL TEXT



30. Preusch MR, Grau AJ, Buggle F; et al. Association between cerebral ischemia and cytotoxin-associated gene-A-bearing strains of Helicobacter pylori. Stroke. 2004;35(8):1800-1804. FREE FULL TEXT



31. Ozdemir FN, Akgul A, Altunoglu A, Bilgic A, Arat Z, Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc. 2007;39(4):990-992. PUBMED



32. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J. 1995;129(4):791-799. PUBMED



33. Tarnacka B, Gromadzka G, Czlonkowska A. Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke. 2002;33(4):936-940. FREE FULL TEXT



34. Kis Z, Sas K, Gyulai Z; et al. Chronic infections and genetic factors in the development of ischemic stroke. New Microbiol. 2007;30(3):213-220. PUBMED



35. Coles KA, Knuiman MW, Plant AJ, Riley TV, Smith DW, Divitini ML. A prospective study of infection and cardiovascular diseases: the Busselton Health Study. Eur J Cardiovasc Prev Rehabil. 2003;10(4):278-282. PUBMED



36. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30(2):299-305. FREE FULL TEXT



37. Guech-Ongey M, Brenner H, Twardella D, Hahmann H, Rothenbacher D. Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes. Int J Cardiol. 2006;111(1):98-103. PUBMED



38. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc. 1983;42(8):2476-2479. PUBMED



39. Ngeh J, Goodbourn C. Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila in elderly patients with stroke (C-PEPS, M-PEPS, L-PEPS): a case-control study on the infectious burden of atypical respiratory pathogens in elderly patients with acute cerebrovascular disease. Stroke. 2005;36(2):259-265. FREE FULL TEXT



40. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: the first National Health and Nutrition Examination Survey and its follow-up study. Arch Intern Med. 2000;160(18):2749-2755. FREE FULL TEXT



41. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. JAMA. 2000;284(11):1406-1410. FREE FULL TEXT



42. O’Connor CM, Dunne MW, Pfeffer MA; et al, Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290(11):1459-1466. FREE FULL TEXT



43. Grayston JT, Kronmal RA, Jackson LA; et al, ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-1645. FREE FULL TEXT



44. Di Napoli M, Schwaninger M, Cappelli R; et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36(6):1316-1329. FREE FULL TEXT

]]> http://www.chsc.or.kr/?post_type=reference&p=1287/feed 0